This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
The Asymptomatic Cardiac Ischemia Pilot (ACIP) Study was a randomized phase 3 treatment study sponsored by the National Heart, Lung, and Blood Institute. The registry lists interventions involving atenolol, nifedipine, diltiazem, isosorbide dinitrate, coronary artery bypass, and percutaneous transluminal coronary angioplasty.
| Feature | ACIP |
|---|---|
| Official title | Asymptomatic Cardiac Ischemia Pilot (ACIP) Study |
| Phase | Phase 3 |
| Status | Completed |
| Start date | 1990-11 |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Conditions | Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| ClinicalTrials.gov | NCT00000478 |
2. Clinical Question
The ACIP record identifies a treatment study in patients and clinical settings involving cardiovascular diseases, coronary disease, heart diseases, and myocardial ischemia. The intervention list combines pharmacologic antianginal therapies with coronary revascularization procedures.
Population
The registry associates the study with cardiovascular diseases, coronary disease, heart diseases, and myocardial ischemia. The title identifies the study as the Asymptomatic Cardiac Ischemia Pilot Study.
Interventions
Atenolol, nifedipine, diltiazem, isosorbide dinitrate, coronary artery bypass, and percutaneous transluminal coronary angioplasty are listed as interventions.
Comparator
The registry record identifies the study as randomized but does not provide a comparator description in the information represented here.
Primary question
The registry identifies treatment as the primary purpose, but it does not register a primary endpoint or state a specific primary statistical comparison in the available record.
3. Trial Design
Randomization is the central statistical design feature that is explicitly identified in the registry. Its importance is causal: when treatment assignment is randomized, systematic differences between treatment groups are controlled in expectation by the randomization process rather than by statistical adjustment alone.
The record does not specify the randomization ratio, number of study arms, masking, study locations, enrollment target, stratification factors, follow-up schedule, or analysis populations. Those details are therefore not used to characterize the design beyond what is explicitly registered.
4. Interventions
Drug therapies
- Atenolol
- Nifedipine
- Diltiazem
- Isosorbide dinitrate
Procedural therapies
- Coronary artery bypass
- Angioplasty, transluminal, percutaneous coronary
From a statistical-design perspective, the intervention list indicates that the study involved more than one therapeutic strategy and included both drug and procedure interventions. The registry information represented here does not specify how these interventions were grouped into randomized arms or which intervention combinations formed the formal treatment comparisons.
5. Endpoints
The ClinicalTrials.gov record represented here contains no registered primary endpoints. Consequently, there is no endpoint definition, measurement scale, assessment schedule, or primary time frame that can be reported from the registry.
| Endpoint element | ClinicalTrials.gov record |
|---|---|
| Registered primary endpoints | None reported |
| Endpoint definitions | Not reported in the record represented here |
| Primary endpoint time frames | Not reported |
| Endpoint-specific analysis | Not reported |
This is an important distinction between a trial being registered and a trial having a fully specified statistical analysis available in the registry. A randomized design establishes how treatment assignment was generated, but statistical interpretation still requires clearly defined outcomes and their measurement rules.
6. Statistical Methodology
The registry identifies ACIP as randomized and phase 3 with a treatment purpose, but it does not post statistical analyses or registered primary endpoints in the information represented here. Therefore, an endpoint-specific statistical method cannot be identified from the registry.
Randomization
Randomization provides the foundation for comparing treatment groups. Under proper random assignment, treatment assignment is independent of measured and unmeasured patient characteristics in expectation. This is what allows a difference between randomized groups to be interpreted as a treatment-assignment effect, subject to adherence, follow-up, missingness, and other aspects of the actual trial conduct.
The exact statistical form depends on the endpoint. A continuous endpoint might use a difference in means, a binary endpoint might use a risk difference or risk ratio, and a time-to-event endpoint might use a hazard ratio or survival-probability difference.
Why the endpoint determines the method
There is no single statistical test that is appropriate for every clinical endpoint. The outcome's scale, distribution, timing, censoring structure, and estimand determine the analysis. For example, a binary outcome can be summarized with event proportions, while a time-to-event outcome requires methods that account for different lengths of follow-up and censoring.
Analysis populations
The registry information represented here does not identify an intention-to-treat population, per-protocol population, as-treated population, safety population, or another analysis set. In a randomized trial, defining the analysis population is important because excluding randomized participants after treatment assignment can alter the comparability created by randomization.
Statistical significance and effect size
A p-value, when reported, addresses the compatibility of observed data with a specified null hypothesis under a particular statistical model. It does not by itself describe the magnitude or clinical importance of an effect. An effect estimate and an appropriate confidence interval are needed to describe magnitude and precision.
7. Planned Analysis
The registry identifies ACIP as a randomized phase 3 treatment study, but no primary endpoint is registered and no formal statistical analysis is posted in the record represented here. Results have not been posted on ClinicalTrials.gov.
How an endpoint would normally be analysed
The appropriate analysis would depend first on the prespecified endpoint. For a binary endpoint, the analysis would generally compare event probabilities or an appropriate relative measure between randomized groups. For a continuous endpoint, a treatment-group difference or model-based contrast could be used. For a time-to-event endpoint, Kaplan-Meier estimation and a model or test appropriate to the prespecified estimand could be used. These are general statistical frameworks; the registry does not identify which one was prespecified for ACIP.
First question
What clinical outcome was prespecified as the primary endpoint?
Second question
What treatment contrast was defined by the randomized allocation?
Third question
What analysis population and estimand were specified?
Fourth question
What statistical model or test was prespecified for that endpoint?
Those questions are necessary before interpreting a treatment effect quantitatively. Without a registered endpoint and posted analysis, the available registry record establishes the broad trial design but does not provide the statistical specification needed for an endpoint-level result.
8. Statistical Methods Explained
Why does randomization matter statistically?
Randomization separates treatment assignment from prognostic characteristics in expectation. This reduces confounding because the treatment groups are created by the allocation mechanism rather than by patient or investigator choice. Statistical adjustment can supplement a randomized design, but it does not replace the role of randomization.
What does "phase 3" tell us about the statistics?
Phase 3 identifies the development phase of the clinical trial; it does not specify a particular statistical test. The statistical analysis still depends on the endpoint, estimand, treatment contrast, follow-up, and analysis population.
Why is the missing primary endpoint important?
The primary endpoint determines what the trial is principally designed to estimate or test. Without that definition, there is no single treatment effect that can be identified as the primary result. Different endpoints can require fundamentally different statistical methods and can answer different clinical questions.
Why can't a randomized trial be summarized by its intervention list alone?
An intervention identifies what was administered or studied, but a statistical comparison requires a defined contrast. If the registry does not specify which interventions were assigned together, which were compared, or how patients were allocated, the intervention list alone is insufficient to reconstruct the randomized comparison.
How would a time-to-event endpoint normally be handled?
If the prespecified outcome were time to an event, methods such as Kaplan-Meier estimation could account for right censoring, while a suitable hypothesis test or regression model could compare randomized groups. The specific estimand and assumptions would need to be established from the endpoint definition and statistical analysis plan.
Why is a confidence interval useful?
A confidence interval describes the statistical precision of an effect estimate under the chosen model and sampling framework. It complements the point estimate by showing how much uncertainty remains. It does not describe the range of outcomes that individual patients will experience.
9. Randomization and Causal Interpretation
The randomized allocation reported by the registry is statistically important because it establishes a prospective comparison rather than an observational comparison. If treatment assignment is implemented according to the randomized design, differences in outcomes between randomized groups can be interpreted in relation to the assigned treatment strategy rather than simply to baseline differences between patients who chose different therapies.
Randomization supports causal inference by making treatment assignment independent of prognostic factors in expectation. It does not guarantee identical groups in every finite sample, and it does not eliminate problems caused by missing outcomes, treatment deviations, crossover, or incomplete follow-up.
The absence of a reported enrollment number also limits the ability to evaluate the statistical information content of the study. Sample size affects standard errors, confidence-interval width, statistical power, and the precision of treatment-effect estimates.
10. Phase 3 Statistical Context
A phase 3 randomized treatment trial generally places substantial emphasis on prespecified confirmatory comparisons. The statistical interpretation of such a study normally depends on a prospectively defined endpoint hierarchy, analysis population, estimand, type I error framework, and sample-size justification.
| Statistical component | Role in a randomized phase 3 study | ACIP registry information |
|---|---|---|
| Randomization | Creates the treatment comparison | Reported |
| Primary endpoint | Defines the principal treatment question | Not reported |
| Sample size | Determines information and statistical precision | Not reported |
| Analysis population | Defines which randomized participants contribute to an analysis | Not reported |
| Statistical test/model | Provides the formal framework for estimating or testing the treatment effect | Not reported |
| Multiplicity strategy | Controls type I error when multiple confirmatory hypotheses are tested | Not reported |
This framework illustrates why a trial's phase and randomized designation are informative but not sufficient to reconstruct its statistical analysis. The missing components determine how evidence from the trial would be quantified and interpreted.
11. Interventions and Statistical Comparability
The combination of pharmacologic and procedural interventions creates an additional design issue: the meaning of a treatment effect depends on the exact intervention contrast. Comparing a drug strategy with a revascularization strategy answers a different question from comparing two drugs, and comparing combination strategies answers a different question again.
Drug strategies
Atenolol, nifedipine, diltiazem, and isosorbide dinitrate are listed as drug interventions.
Procedural strategies
Coronary artery bypass and percutaneous transluminal coronary angioplasty are listed as procedural interventions.
Statistical contrast
The treatment effect must be defined relative to a specific randomized comparison rather than to the intervention list as a whole.
Estimand
The clinical question determines whether the target is an effect of treatment assignment, treatment received, or another treatment strategy.
For this reason, the absence of an identified randomized arm structure is not a minor reporting detail. It prevents the intervention list from being converted into a specific numerical treatment comparison.
12. Missingness, Follow-up, and Censoring
Clinical trials frequently encounter incomplete follow-up, withdrawal, treatment discontinuation, and other forms of missing outcome information. The statistical consequences depend on the endpoint and the mechanism producing the missing data.
For a time-to-event endpoint, a participant who has not experienced the event by the last known assessment may contribute information through that time and then be censored. For a continuous outcome, missing observations generally require a prespecified analysis approach. For binary outcomes, the handling of participants without an evaluable outcome can directly affect the estimated event proportion.
13. Multiplicity and Multiple Comparisons
The intervention list contains multiple therapies and procedures, but the registry information represented here does not specify the number of randomized treatment groups, primary hypotheses, secondary endpoints, or formal testing hierarchy.
Multiplicity becomes important whenever several hypotheses are tested using the same overall type I error budget. If several comparisons are treated as confirmatory, the statistical design must specify how false-positive error is controlled. Common approaches include hierarchical testing, alpha allocation, or other prespecified multiplicity procedures.
Without the registered endpoint hierarchy or statistical analysis plan, no particular multiplicity procedure can be attributed to ACIP.
14. Safety Analysis Framework
The registry identifies ACIP as a treatment study and lists several pharmacologic and procedural interventions, but the available record does not provide serious adverse-event counts, adverse-event rates, safety endpoints, exposure durations, or a safety analysis population.
| Safety element | Registry information |
|---|---|
| Serious adverse events by arm | Not reported |
| Adverse-event rates | Not reported |
| Safety endpoint definitions | Not reported |
| Safety analysis population | Not reported |
| Exposure duration | Not reported |
Safety is statistically distinct from efficacy. Treatment assignment can be associated with both beneficial and harmful outcomes, and safety analyses generally require careful accounting for exposure, event severity, event timing, and treatment discontinuation.
15. ClinicalTrials.gov Record Structure and Statistical Interpretation
A registry record serves several purposes: identifying the study, describing its design, documenting its interventions and conditions, and making selected study information publicly accessible. Statistical interpretation requires more than these descriptive fields because an analysis needs a defined estimand and outcome.
| Information | Why it matters statistically |
|---|---|
| Randomized allocation | Defines the basis for causal comparison |
| Intervention | Defines what treatment strategy is being studied |
| Comparator | Defines the reference treatment strategy |
| Primary endpoint | Defines the principal outcome of interest |
| Analysis population | Defines who contributes to the statistical analysis |
| Statistical method | Defines how the treatment effect is estimated or tested |
| Sample size | Determines statistical information and precision |
For ACIP, the registry clearly identifies randomization, phase, treatment purpose, interventions, conditions, sponsor, and study status. It does not provide the endpoint and analysis details needed to extend that description into a quantitative endpoint-level statistical result.
16. Limitations
- No registered primary endpoints: the ClinicalTrials.gov record represented here does not identify a primary endpoint or its definition.
- No posted statistical analyses: the registry does not contain formal statistical analyses for the study.
- No enrollment number: the record does not report the study enrollment number in the information represented here, limiting assessment of statistical precision and power.
- No randomized arm structure: the intervention list does not identify the exact randomized treatment-group composition or allocation ratio.
- No comparator description: the available record identifies randomized allocation but does not specify the comparator structure.
- No analysis population: the record does not identify an intention-to-treat, per-protocol, as-treated, or safety population.
- No statistical model: the registry does not identify the statistical tests, regression models, confidence-interval methods, or estimands used for the study.
- No multiplicity framework: there is no registered information here describing multiple-testing control or a formal endpoint hierarchy.
- No missing-data strategy: the record does not describe imputation, censoring, or other missing-outcome procedures.
- No safety results: serious adverse events and other safety outcomes by treatment arm are not reported in the available registry information.
17. Why This Trial Matters Statistically
ACIP is useful as a statistical teaching case because the registry clearly demonstrates an important principle of clinical-trial interpretation: randomization alone does not define the statistical analysis.
| Concept | How it appears in ACIP |
|---|---|
| Randomization | The registry identifies the allocation as randomized. |
| Phase 3 design | The study is registered as phase 3. |
| Treatment comparison | The primary purpose is treatment. |
| Multiple interventions | Both drug and procedural interventions are listed. |
| Endpoint specification | No registered primary endpoint is reported. |
| Effect estimation | An endpoint-specific effect estimate cannot be identified from the registry. |
| Sample size | Enrollment is not reported in the record represented here. |
| Analysis methods | No formal statistical analyses are posted. |
The study therefore illustrates the difference between design information and analysis information. A randomized trial provides a framework for causal inference, but the statistical evidence still depends on a precisely defined outcome, treatment contrast, estimand, analysis population, and statistical model.
18. A Practical Statistical Reading of ACIP
What is established?
ACIP is a completed, randomized phase 3 treatment study sponsored by the National Heart, Lung, and Blood Institute.
What was studied?
The registry lists four drug interventions and two coronary revascularization procedures in the setting of cardiovascular and ischemic heart disease.
What is not established by this record?
The available registry information does not identify the primary endpoint, randomized arm structure, sample size, or formal statistical analysis.
What would an analysis require?
A defined treatment contrast, endpoint, estimand, analysis population, and prespecified statistical method would be required for quantitative interpretation.
This distinction prevents a common statistical error: treating a trial title and intervention list as though they were equivalent to a statistical analysis plan. They are not. The statistical question begins with the clinical endpoint and the randomized comparison.
19. Sources
- ClinicalTrials.gov: NCT00000478 — Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.
Continue through the Clinical Biostats clinical trial library
Explore additional clinical-trial analyses and statistical resources from Clinical Biostats.
20. Record Summary
ACIP is registered as a completed phase 3 randomized treatment study beginning in 1990-11 and sponsored by the National Heart, Lung, and Blood Institute. The study concerns cardiovascular diseases, coronary disease, heart diseases, and myocardial ischemia, and its intervention list includes atenolol, nifedipine, diltiazem, isosorbide dinitrate, coronary artery bypass, and percutaneous transluminal coronary angioplasty.
From a statistical perspective, the most important feature explicitly recorded is randomized allocation. At the same time, the registry record represented here does not report enrollment, registered primary endpoints, randomized arm structure, comparator details, analysis populations, statistical methods, or posted statistical analyses. Results have not been posted on ClinicalTrials.gov.
The appropriate statistical interpretation is therefore centered on the design principles rather than an unsupported numerical efficacy estimate. Randomization provides the basis for causal comparison, while the absent endpoint and analysis specifications prevent identification of a primary treatment effect from the registry information alone.